Literature DB >> 27261687

Neuromyelitis Optica Spectrum Disorders.

Ilana Katz Sand.   

Abstract

PURPOSE OF REVIEW: This article provides a practical approach for providers caring for patients with neuromyelitis optica (NMO) spectrum disorders. Clinical and imaging features, diagnostic criteria, treatment of acute exacerbations, chronic preventive therapy, and symptom management in NMO spectrum disorders are discussed. RECENT
FINDINGS: The rapid pace of research in NMO spectrum disorders has led to many recent advances. A broader understanding of the clinical spectrum of the disease as well as improvements in anti-aquaporin-4 antibody assays have led to recent revision of the diagnostic criteria. Several recent studies have expanded the knowledge base regarding the efficacy and safety of current therapies for NMO spectrum disorders.
SUMMARY: An NMO spectrum disorder is an inflammatory disorder affecting the central nervous system, previously thought to be closely related to multiple sclerosis but more recently demonstrated to represent a distinct clinical and pathophysiologic entity. As NMO spectrum disorders carry significant morbidity and, at times, mortality, prompt and accurate diagnosis followed by swift initiation of therapy for both treatment of acute exacerbations and prevention of further relapses is critical. This article provides a practical approach to the diagnosis and management of NMO spectrum disorders.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27261687     DOI: 10.1212/CON.0000000000000337

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  10 in total

1.  Practice current: How do you treat neuromyelitis optica?

Authors:  Aravind Ganesh
Journal:  Neurol Clin Pract       Date:  2017-04

2.  Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis.

Authors:  E Bulut; J Karakaya; S Salama; M Levy; T A G M Huisman; I Izbudak
Journal:  AJNR Am J Neuroradiol       Date:  2019-03-07       Impact factor: 3.825

3.  Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.

Authors:  Zahra Nikoo; Shervin Badihian; Vahid Shaygannejad; Nasrin Asgari; Fereshteh Ashtari
Journal:  J Neurol       Date:  2017-08-22       Impact factor: 4.849

Review 4.  Cognitive dysfunction in adult patients with neuromyelitis optica: a systematic review and meta-analysis.

Authors:  Hao Meng; Jun Xu; Chenling Pan; Jiaxing Cheng; Yue Hu; Yin Hong; Yuehai Shen; Hua Dai
Journal:  J Neurol       Date:  2016-12-01       Impact factor: 4.849

5.  Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.

Authors:  V Shaygannejad; E Fayyazi; S Badihian; O Mirmosayyeb; N Manouchehri; F Ashtari; N Asgari
Journal:  J Neurol       Date:  2019-01-11       Impact factor: 6.682

6.  Higher Disease and Pain Severity and Fatigue and Lower Balance Skills Are Associated with Higher Prevalence of Falling among Individuals with the Inflammatory Disease of Neuromyelitis Optica Spectrum Disorder (NMOSD).

Authors:  Mahdi Barzegar; Dena Sadeghi Bahmani; Omid Mirmosayyeb; Reyhaneh Azarbayejani; Alireza Afshari-Safavi; Saeed Vaheb; Nasim Nehzat; Afshin Dana; Vahid Shaygannejad; Robert W Motl; Serge Brand
Journal:  J Clin Med       Date:  2020-11-09       Impact factor: 4.241

7.  Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder from Ethiopia: A Case Report.

Authors:  Dereje Melka
Journal:  Ethiop J Health Sci       Date:  2020-09

8.  Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset.

Authors:  Dena Sadeghi-Bahmani; Mahdi Barzegar; Omid Mirmosayyeb; Saeed Vaheb; Nasim Nehzat; Vahid Shaygannejad; Serge Brand
Journal:  J Clin Med       Date:  2022-01-29       Impact factor: 4.241

9.  Predictive Value of Serum Antibodies and Point Mutations of AQP4, AQP1 and MOG in A Cohort of Spanish Patients with Neuromyelitis Optica Spectrum Disorders.

Authors:  Pablo García-Miranda; Francisco J Morón-Civanto; Maria Del Mar Martínez-Olivo; Nela Suárez-Luna; Reposo Ramírez-Lorca; Lucía Lebrato-Hernández; Raquel Lamas-Pérez; Guillermo Navarro; Javier Abril-Jaramillo; Maria Isabel García-Sánchez; José Luis Casado-Chocán; Antonio José Uclés-Sánchez; Mercedes Romera; Miriam Echevarría; María Díaz-Sánchez
Journal:  Int J Mol Sci       Date:  2019-11-19       Impact factor: 5.923

Review 10.  Cognitive impairment in NMOSD-More questions than answers.

Authors:  Dominika Czarnecka; Magdalena Oset; Iwona Karlińska; Mariusz Stasiołek
Journal:  Brain Behav       Date:  2020-10-06       Impact factor: 2.708

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.